Perennial Real Estate of Singapore announced a $1.2B joint venture to develop hospital-centered mixed-use developments in China.
January 6, 2017
Deals and Financings
- Perennial Real Estate of Singapore announced a $1.2 billion joint venture to develop hospital-centered mixed-use developments in China;
- Jiangsu Hengrui Medicine out-licensed ex-China rights for a novel JAK inhibitor to Arcutis Pharma of California in a $233 million deal;
- SomaLogic of Colorado raised $200 million to measure human protein levels in a funding anchored by China’s iCarbonX;
- Aslan Pharma of Singapore acquired global control of varlitinib, its lead oncology drug, from Array BioPharma in a $129 million agreement;
- Sansure Biotech of Changsha, a diagnostics company, raised $77 Million in a funding round led by Lilly Asia Ventures and Highlight Capital;
- KBP Biosciences of Jinan closed a $76 million Series A financing to support its pipeline and open a global Philadelphia headquarters;
- Beijing’s Genetron Health, a precision medicine oncology company, raised $61 million in a C round led by Zhongjin Kangrui Medical Industrial Fund;
- Zhejiang DTRM Biopharma announced a $60 million Series A round to support clinical trials of its lead cancer candidate, a BTK inhibitor;
- ApolloBio of Beijing signed an amended $43 million deal for China rights to Inovio’s HPV pre-cancer immunotherapy;
- CMAB Biopharma completed a $38 million Series A funding for its biologic CRO/CMO operations in Suzhou BioBay Park; C-Bridge led the round;
- Miracor Medical, an Austrian medical device company, closed a $30 million D funding round, led by Ming Capital of Shenzhen;
- Laviana Pharma, a CRO/CMO with subsidiaries in Beijing and Tianjin, closed a $15 million Series B funding led by Shenzhen Huayi Capital;
- Genostics of Hong Kong invested $13.5 million in UK-based Oncimmune for China rights to its blood-based cancer testing platform;
- Illumina partnered with China’s KingMed Diagnostics to develop China oncology diagnostics;
- Xinogen (Hong Kong) Pharma will collaborate with Montreal’s Angiochem to develop a treatment for leptomeningeal carcinomatosis in China.
Stock Symbols: (SGX: 40S) (SHA: 600276) (TT: 6497) (NSDQ: ARRY) (NEEQ: 430187) (NSDQ: INO) (NEEQ: 838853) (NSDQ: ILMN) (SHA: 603882)
